Nifty
:
24834.85
Sensex
:
81332.72
428.75 (1.76%)
1292.92 (1.62%)
Nifty
Sensex
:
:
24834.85
81332.72
428.75 (1.76%)
1292.92 (1.62%)

Biocon Ltd.

Pharmaceuticals & Drugs - Global

Rating :
61/99

BSE: 532523 | NSE: BIOCON

NSE BSE
370.20
05-Jul-2024
  • Open
  • High
  • Low
  • Previous Close
  •  361.00
  •  371.40
  •  360.10
  •  361.30
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  7658844
  •  28184.64
  •  376.80
  •  217.50

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 44,254.12
  • 43.28
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 57,725.02
  • 0.14%
  • 2.27

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 60.64%
  • 1.50%
  • 14.64%
  • FII
  • DII
  • Others
  • 5.9%
  • 14.20%
  • 3.12%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 16.92
  • 18.55
  • 21.71

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 16.47
  • 20.52
  • 16.45

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.47
  • 5.64
  • 16.40

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 59.08
  • 62.47
  • 62.05

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.93
  • 4.54
  • 3.40

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.43
  • 20.03
  • 16.42

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Net Sales
3,917.10
3,773.90
3.79%
3,953.70
2,941.10
34.43%
3,462.30
2,319.70
49.26%
3,422.60
2,139.50
59.97%
Expenses
3,001.20
2,776.60
8.09%
3,026.90
2,296.80
31.79%
2,720.70
1,849.00
47.14%
2,708.20
1,740.10
55.63%
EBITDA
915.90
997.30
-8.16%
926.80
644.30
43.85%
741.60
470.70
57.55%
714.40
399.40
78.87%
EBIDTM
23.38%
26.43%
23.44%
21.91%
21.42%
20.29%
20.87%
18.67%
Other Income
48.60
154.90
-68.62%
565.50
78.60
619.47%
157.90
64.50
144.81%
93.50
77.90
20.03%
Interest
227.00
248.80
-8.76%
266.70
120.30
121.70%
247.70
30.00
725.67%
233.00
19.90
1,070.85%
Depreciation
407.00
363.70
11.91%
414.50
301.10
37.66%
389.30
230.80
68.67%
358.00
217.50
64.60%
PBT
321.70
536.70
-40.06%
832.30
30.10
2,665.12%
238.50
257.40
-7.34%
216.90
239.90
-9.59%
Tax
96.10
82.10
17.05%
54.90
-4.80
-
41.60
147.30
-71.76%
34.80
29.50
17.97%
PAT
225.60
454.60
-50.37%
777.40
34.90
2,127.51%
196.90
110.10
78.84%
182.10
210.40
-13.45%
PATM
5.76%
12.05%
19.66%
1.19%
5.69%
4.75%
5.32%
9.83%
EPS
1.13
2.61
-56.70%
5.50
-0.35
-
1.05
0.39
169.23%
0.84
1.20
-30.00%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
-
14,755.70
11,174.20
8,184.00
7,143.10
6,300.50
5,514.40
4,123.40
3,891.10
3,347.40
3,089.80
Net Sales Growth
-
32.05%
36.54%
14.57%
13.37%
14.26%
33.73%
5.97%
16.24%
8.34%
 
Cost Of Goods Sold
-
4,897.90
3,663.10
2,718.40
2,243.70
1,989.50
1,896.60
1,636.10
1,446.60
1,290.40
1,255.60
Gross Profit
-
9,857.80
7,511.10
5,465.60
4,899.40
4,311.00
3,617.80
2,487.30
2,444.50
2,057.00
1,834.20
GP Margin
-
66.81%
67.22%
66.78%
68.59%
68.42%
65.61%
60.32%
62.82%
61.45%
59.36%
Total Expenditure
-
11,559.00
9,054.70
6,691.40
5,841.00
5,043.50
4,390.60
3,294.30
2,911.60
2,584.30
2,394.00
Power & Fuel Cost
-
388.90
414.80
316.40
270.30
246.10
239.80
189.00
156.40
184.70
176.70
% Of Sales
-
2.64%
3.71%
3.87%
3.78%
3.91%
4.35%
4.58%
4.02%
5.52%
5.72%
Employee Cost
-
2,664.10
2,181.00
1,880.10
1,741.00
1,458.80
1,165.30
931.10
747.00
610.10
533.40
% Of Sales
-
18.05%
19.52%
22.97%
24.37%
23.15%
21.13%
22.58%
19.20%
18.23%
17.26%
Manufacturing Exp.
-
2,376.90
1,917.20
1,243.50
1,019.20
864.60
721.20
335.70
391.50
203.70
81.20
% Of Sales
-
16.11%
17.16%
15.19%
14.27%
13.72%
13.08%
8.14%
10.06%
6.09%
2.63%
General & Admin Exp.
-
806.00
359.60
181.50
270.50
182.10
53.00
56.80
21.70
144.60
165.70
% Of Sales
-
5.46%
3.22%
2.22%
3.79%
2.89%
0.96%
1.38%
0.56%
4.32%
5.36%
Selling & Distn. Exp.
-
296.60
221.60
243.80
235.90
266.30
277.50
98.20
107.40
100.80
108.70
% Of Sales
-
2.01%
1.98%
2.98%
3.30%
4.23%
5.03%
2.38%
2.76%
3.01%
3.52%
Miscellaneous Exp.
-
128.60
297.40
107.70
60.40
36.10
37.20
47.40
41.00
50.00
108.70
% Of Sales
-
0.87%
2.66%
1.32%
0.85%
0.57%
0.67%
1.15%
1.05%
1.49%
2.35%
EBITDA
-
3,196.70
2,119.50
1,492.60
1,302.10
1,257.00
1,123.80
829.10
979.50
763.10
695.80
EBITDA Margin
-
21.66%
18.97%
18.24%
18.23%
19.95%
20.38%
20.11%
25.17%
22.80%
22.52%
Other Income
-
967.50
768.10
690.30
605.20
507.50
414.30
206.20
157.10
83.90
53.10
Interest
-
974.40
419.00
67.60
57.70
64.90
70.90
61.50
26.00
29.30
8.90
Depreciation
-
1,568.80
1,113.10
814.20
715.10
552.20
447.80
385.10
277.20
248.70
221.00
PBT
-
1,621.00
1,355.50
1,301.10
1,134.50
1,147.40
1,019.40
588.70
833.40
569.00
519.00
Tax
-
227.40
254.10
211.50
221.50
315.10
212.30
156.90
161.60
142.20
95.70
Tax Rate
-
14.13%
23.88%
17.77%
19.31%
25.94%
17.49%
26.65%
19.39%
19.49%
15.33%
PAT
-
1,022.50
462.70
648.40
819.90
777.10
904.40
351.10
595.80
528.70
497.40
PAT before Minority Interest
-
1,297.80
643.00
771.60
925.60
899.80
1,001.70
431.80
671.80
587.40
528.40
Minority Interest
-
-275.30
-180.30
-123.20
-105.70
-122.70
-97.30
-80.70
-76.00
-58.70
-31.00
PAT Margin
-
6.93%
4.14%
7.92%
11.48%
12.33%
16.40%
8.51%
15.31%
15.79%
16.10%
PAT Growth
-
120.99%
-28.64%
-20.92%
5.51%
-14.08%
157.59%
-41.07%
12.69%
6.29%
 
EPS
-
8.52
3.85
5.40
6.83
6.47
7.53
2.92
4.96
4.40
4.14

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
19,783.70
17,866.90
8,432.50
7,626.90
6,705.80
6,098.00
5,180.80
4,837.70
4,033.80
3,270.60
Share Capital
600.30
600.30
600.30
600.00
600.00
300.00
300.00
100.00
100.00
100.00
Total Reserves
18,863.30
16,992.60
7,628.10
6,872.80
5,997.00
5,720.80
4,812.30
4,670.20
3,873.00
3,132.70
Non-Current Liabilities
15,119.80
20,742.30
6,802.70
5,496.90
2,684.70
2,122.30
2,006.50
2,304.60
2,421.30
1,377.90
Secured Loans
11,267.70
13,692.30
2,574.30
1,492.40
1,220.80
1,523.50
1,787.00
2,104.30
2,061.00
758.20
Unsecured Loans
1,664.70
1,598.20
1,424.20
1,469.20
1.40
2.10
2.80
3.90
11.40
11.40
Long Term Provisions
237.60
226.50
91.70
106.20
85.80
66.10
49.30
36.00
29.90
15.00
Current Liabilities
15,358.80
8,510.70
3,828.00
4,210.10
4,008.00
3,038.50
2,141.30
1,678.30
1,665.70
1,554.70
Trade Payables
6,272.00
3,842.00
1,608.50
1,513.90
1,325.10
1,198.30
1,005.30
739.70
609.80
429.30
Other Current Liabilities
6,481.20
1,814.90
1,031.20
1,840.20
1,784.40
1,374.70
870.10
698.20
527.10
706.20
Short Term Borrowings
2,149.20
2,480.20
896.00
594.20
667.60
261.20
130.30
97.20
394.90
261.00
Short Term Provisions
456.40
373.60
292.30
261.80
230.90
204.30
135.60
143.20
133.90
158.20
Total Liabilities
55,753.40
51,741.80
20,100.70
18,214.60
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
Net Block
30,643.60
29,467.70
6,569.00
6,363.90
5,971.10
4,471.00
3,699.50
3,625.10
1,748.30
1,629.90
Gross Block
37,930.10
35,321.40
11,233.00
10,220.90
9,147.40
7,095.00
5,873.80
5,436.10
3,403.60
3,034.20
Accumulated Depreciation
7,287.40
5,853.70
4,664.00
3,857.00
3,176.30
2,624.00
2,174.30
1,811.00
1,655.30
1,404.30
Non Current Assets
40,574.20
39,407.80
11,718.40
10,614.20
8,750.80
6,979.20
5,647.70
5,149.00
4,415.70
3,812.80
Capital Work in Progress
7,993.30
7,317.00
4,110.40
2,800.20
2,196.00
1,898.90
1,302.80
839.20
2,239.50
1,676.40
Non Current Investment
684.10
742.30
370.20
743.20
108.50
182.50
63.80
188.80
26.80
0.00
Long Term Loans & Adv.
892.50
683.20
483.80
436.40
402.00
335.80
437.20
319.70
350.10
336.90
Other Non Current Assets
360.70
1,197.60
185.00
270.50
73.20
91.00
144.40
176.20
51.00
169.60
Current Assets
15,179.20
12,334.00
8,382.30
7,600.40
5,325.00
4,888.50
4,148.60
4,047.70
3,970.90
2,562.60
Current Investments
315.60
1,326.50
1,217.70
1,208.70
857.60
829.30
611.40
1,065.00
874.70
230.30
Inventories
4,943.90
4,243.70
2,298.20
1,866.60
1,435.90
1,031.60
722.50
635.30
542.40
452.70
Sundry Debtors
6,230.60
3,573.20
2,058.20
1,503.30
1,223.70
1,291.80
1,063.90
883.20
714.50
770.50
Cash & Bank
2,258.70
2,400.10
1,747.50
2,015.40
998.60
1,057.20
1,322.80
1,044.30
1,538.60
937.50
Other Current Assets
1,430.40
334.10
660.20
713.10
809.20
678.60
428.00
419.90
300.70
171.60
Short Term Loans & Adv.
1,096.00
456.40
400.50
293.30
265.60
153.10
54.70
24.10
134.70
75.80
Net Current Assets
-179.60
3,823.30
4,554.30
3,390.30
1,317.00
1,850.00
2,007.30
2,369.40
2,305.20
1,007.90
Total Assets
55,753.40
51,741.80
20,100.70
18,214.60
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
2,953.90
1,852.50
1,176.60
1,159.70
1,283.10
1,154.60
662.10
640.00
370.60
210.70
PBT
1,525.20
897.10
983.10
1,067.70
870.90
1,002.60
610.00
849.70
751.30
624.10
Adjustment
2,356.20
1,685.00
1,245.00
709.60
921.40
472.60
355.70
204.40
42.00
74.00
Changes in Working Capital
-635.20
-501.00
-789.50
-423.80
-165.10
-29.10
-106.50
-211.10
-176.20
-354.00
Cash after chg. in Working capital
3,246.20
2,081.10
1,438.60
1,353.50
1,627.20
1,446.10
859.20
843.00
617.10
344.10
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-292.30
-228.60
-262.00
-193.80
-344.10
-291.50
-197.10
-203.00
-246.50
-133.40
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,004.50
-14,281.80
-1,699.10
-3,624.70
-1,558.90
-713.80
-684.00
-498.50
-1,141.70
-508.70
Net Fixed Assets
-323.20
-260.40
-284.70
-130.90
744.40
-280.60
-177.90
-215.90
-216.90
-57.90
Net Investments
-47.80
-3,990.70
202.20
-456.90
-890.30
107.80
-310.70
-79.30
-3,688.10
328.50
Others
-633.50
-10,030.70
-1,616.60
-3,036.90
-1,413.00
-541.00
-195.40
-203.30
2,763.30
-779.30
Cash from Financing Activity
-2,332.70
13,048.70
242.10
2,564.00
387.60
-241.70
-239.70
-177.50
1,067.60
186.20
Net Cash Inflow / Outflow
-383.30
619.40
-280.40
99.00
111.80
199.10
-261.60
-36.00
296.50
-111.80
Opening Cash & Equivalents
1,299.90
653.70
897.00
824.70
659.30
449.00
710.20
757.50
457.50
557.00
Closing Cash & Equivalent
919.50
1,294.80
653.70
897.00
824.70
659.30
449.00
710.20
757.50
462.60

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
162.11
146.53
68.53
62.27
54.97
50.17
42.59
39.74
33.10
26.93
ROA
2.41%
1.79%
4.03%
5.73%
6.94%
9.25%
4.55%
7.64%
7.96%
8.72%
ROE
7.00%
4.98%
9.83%
13.16%
14.26%
18.00%
8.74%
15.37%
16.31%
17.22%
ROCE
7.03%
5.37%
8.30%
11.30%
14.35%
16.11%
8.92%
12.59%
13.93%
15.30%
Fixed Asset Turnover
0.41
0.48
0.77
0.74
0.78
0.85
0.73
0.89
1.05
1.09
Receivable days
119.85
91.14
79.19
69.67
72.86
77.96
86.05
74.35
80.16
80.09
Inventory Days
112.31
105.87
92.60
84.38
71.47
58.05
60.00
54.81
53.71
48.47
Payable days
376.86
271.55
209.62
230.92
81.60
81.98
87.98
78.68
71.28
58.15
Cash Conversion Cycle
-144.70
-74.54
-37.84
-76.87
62.74
54.04
58.07
50.48
62.59
70.42
Total Debt/Equity
0.81
1.01
0.60
0.58
0.40
0.40
0.44
0.48
0.62
0.35
Interest Cover
2.57
3.14
15.54
20.88
19.72
18.12
10.57
33.05
25.90
71.12

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • Biocon’s arm gets EMA’s nod to manufacture biosimilar Bevacizumab at Bengaluru facility
    24th Jun 2024, 16:58 PM

    The facility has previously been approved to manufacture biosimilar Trastuzumab in September 2022

    Read More
  • USFDA concludes GMP inspection of Biocon’s API facility in Visakhapatnam
    24th Jun 2024, 16:41 PM

    Four observations were cited at the end of the Inspection

    Read More
  • Biocon gets nod for Micafungin from USFDA
    4th Jun 2024, 09:28 AM

    The approval further strengthens Biocon’s portfolio of vertically integrated, complex drug products

    Read More
  • Biocon signs exclusive licensing, supply agreement with Handok
    24th May 2024, 09:22 AM

    Handok is amongst Korea’s leading companies in the management of diabetes, offering a host of solutions from diagnosis to treatment and care

    Read More
  • Biocon’s arm gets USFDA’s nod for Yesafili
    21st May 2024, 09:30 AM

    The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States

    Read More
  • Biocon reports 46% fall in Q4 consolidated net profit
    17th May 2024, 11:43 AM

    Total consolidated income of the company increased by 0.94% at Rs 3965.70 crore for Q4FY24

    Read More
  • Biocon - Quarterly Results
    16th May 2024, 17:16 PM

    Read More
  • Biocon signs exclusive distribution, supply agreement with Medix
    13th May 2024, 09:25 AM

    The company has signed agreement for the commercialization of its vertically integrated drug product, Liraglutide

    Read More
  • Biocon signs licensing and supply agreement with Biomm S.A.
    18th Apr 2024, 09:17 AM

    Biomm is Brazil’s first and only biotechnology focused company, providing high quality healthcare to patients with chronic conditions and enhancing access to the latest technologies and treatments

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.